Review
Published · Updated · 1 min read
Cardiotoxicity of venetoclax and modern hematologic cancer therapy: the cardiologist’s role
What it means for practice
Cardiovascular risk assessment and management during modern hematologic cancer therapy require collaboration among hematologists, oncologists, and cardiologists to balance treatment efficacy and cardiovascular safety.
Summary
Scope of the review
The article addresses cardiovascular complications associated with modern treatment of patients with hematologic malignancies. It covers targeted therapies, immunotherapies, CAR T-cell therapies, and hematopoietic stem cell transplantation. Particular attention is given to the cardiotoxic effects of immune checkpoint inhibitors, BTK inhibitors, and venetoclax.
Implications for clinical practice
The review outlines current approaches to cardiovascular risk assessment and management in the context of anticancer treatment. Its central theme is multidisciplinary care involving hematologists, oncologists, and cardiologists. This collaboration is presented as an important component of balancing the efficacy of hematologic cancer therapy against cardiovascular safety. The cardiologist’s role is considered within shared patient management rather than separately from the underlying cancer treatment.
Limits of the available information
The supplied abstract provides no complication rates, quantitative risk estimates, or specific assessment and treatment algorithms. It therefore does not support comparisons of cardiotoxicity between individual drugs or selection of a monitoring regimen for an individual patient.
Source
-
Кардіоваскулярні ускладнення сучасної терапії в онкогематології: роль кардіолога в мультидисциплінарному веденні пацієнтів.
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer
